Axsome Therapeutics News and Activities

Axsome Therapeutics is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Axsome Therapeutics is a company listed under the stock ticker AXSM (US).

View the org chart displaying its 19 main executives

Most searched biographies at Axsome Therapeutics

• Herriot Tabuteau, Chief Executive Officer and Director
• Mark Coleman, Director
• Mark Saad, Director

Create your alert
to follow the executive moves at Axsome Therapeutics.

Axsome Therapeutics has 2,339 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).
• The new name of Garuda Therapeutics is Stratus Therapeutics. (posted on May 12 2025).
• Jade Biosciences and Aerovate Therapeutics have announced they will merge  (posted on April 30 2025)..

Popular contacts in Biotechnology

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Deepika Verma - Associate Director of Data Science and Digitalization at Wheeler Bio
• Steven Gillis - Chairman of the Board at VBI Vaccines

Learn more about the Biotechnology industry

Press releases by Axsome Therapeutics

• Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022 | Axsome Therapeutics, Inc.
• Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders | Axsome Therapeutics, Inc.
• Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event | Axsome Therapeutics, Inc.
• Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting | Axsome Therapeutics, Inc.
• Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder | Axsome Therapeutics, Inc.
• Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting | Axs
• Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry | Axsome Therapeutics, Inc.
• Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry | Axsome Therapeutics, Inc.
• Axsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month | Axsome Therapeutics, Inc.
• Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea | Axsome Therapeutics, Inc.
• View more press releases Close

Social media about Axsome Therapeutics

• Axsome Therapeutics on Wikipedia, Google News & Yahoo Finance
• Axsome Therapeutics on LinkedIn, Twitter & YouTube